Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) FCF Margin (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed FCF Margin for 6 consecutive years, with 640.94% as the latest value for Q4 2025.

  • Quarterly FCF Margin changed N/A to 640.94% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1535.98% through Dec 2025, up 97351.0% year-over-year, with the annual reading at 1536.08% for FY2025, 97341.0% up from the prior year.
  • FCF Margin for Q4 2025 was 640.94% at Relay Therapeutics, up from 8166.47% in the prior quarter.
  • The five-year high for FCF Margin was 8930600.0% in Q4 2023, with the low at 58910.92% in Q2 2023.
  • Average FCF Margin over 5 years is 546542.61%, with a median of 7720.21% recorded in 2021.
  • The sharpest move saw FCF Margin plummeted -67524988bps in 2021, then skyrocketed 895407628bps in 2023.
  • Over 5 years, FCF Margin stood at 7609.35% in 2021, then crashed by -209bps to 23476.28% in 2022, then skyrocketed by 38141bps to 8930600.0% in 2023, then crashed by -100bps to 520.67% in 2024, then decreased by -23bps to 640.94% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 640.94%, 8166.47%, and 958.38% for Q4 2025, Q2 2025, and Q1 2025 respectively.